Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Cancer Epidemiology Biomarkers & Prevention
DOI: 10.1158/1055-9965.EPI-22-0941
2023

Single-cell transcriptomic analysis of endometriosis
Nature Genetics
DOI: 10.1038/S41588-022-01254-1
2023

Immunohistochemical Profiles Including p53, MMR, PR and CTNNB1 are Associated with Survival of Patients Diagnosed with Ovarian Endometrioid Carcinoma
Modern Pathology
2022

The proteome of clear cell ovarian carcinoma
The Journal of Pathology
DOI: 10.1002/PATH.6006
2022

Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features
Journal of Pathology Clinical Research
DOI: 10.1002/CJP2.243
2022

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-21-3817
2022

Metastasis in endometriosis: targeted sequencing suggests non-malignancy associated endometriosis is capable of wide dissemination
Geburtshilfe und Frauenheilkunde
DOI: 10.1055/S-0042-1756999
2022

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Virchows Archiv
DOI: 10.1007/S00428-021-03232-0
2022

Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes
Fertility and Sterility
DOI: 10.1016/J.FERTNSTERT.2022.05.030
2022

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8⁺ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas
The Journal of Pathology
DOI: 10.1002/PATH.5849
2022

Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?
Gynecologic Oncology Reports
DOI: 10.1016/J.GORE.2022.101076
2022

Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia
The Journal of Immunology
DOI: 10.4049/JIMMUNOL.208.SUPP.179.04
2022

Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma
International Journal of Gynecological Pathology
DOI: 10.1097/PGP.0000000000000780
2022

LYMPHADENECTOMY IN ENDOMETRIOID OVARIAN CARCINOMA PATIENTS WITH EARLY STAGE DISEASE: RESULTS FROM THE LEOPARD TRIAL
International Journal of Gynecological Cancer
DOI: 10.1136/IJGC-2022-IGCS.33
2022

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-22-1206
2022

Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer
Gynecologic Oncology
DOI: 10.1016/J.YGYNO.2022.07.020
2022

Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping
Reproductive Sciences
Paul J. Yong and Aline Talhouk and Michael S. Anglesio
DOI: 10.1007/s43032-020-00451-9
10/2021

Pathogenesis of bowel endometriosis
Best Practice & Research Clinical Obstetrics & Gynaecology
Paul J. Yong and Mohamed A. Bedaiwy and Fahad Alotaibi and Michael S. Anglesio
DOI: 10.1016/j.bpobgyn.2020.05.009
03/2021

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
Modern Pathology
DOI: 10.1038/S41379-020-0618-9
2021

NUCLEAR FEATURES ALLOW FOR HIGHLY SENSITIVE SELECTION OF ENDOMETRIAL CARCINOMAS FOR P53 TESTING
International Journal of Gynecological Cancer
DOI: 10.1136/IJGC-2021-IGCS.173
2021

Pattern of invasion in stage I mucinous ovarian cancer is prognostic within 2-years of diagnosis
Asia-Pacific Journal of Clinical Oncology
2021

Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
Journal of Cancer Research and Clinical Oncology
DOI: 10.1007/S00432-021-03558-X
2021

Prognostic and theragnostic biomarkers in ovarian clear cell carcinoma
Katharina Wiedemeyer and Linyuan Wang and Eun Young Kang and Shuhong Liu and Young Ou and Linda E. Kelemen and Lukas Feil and Michael S. Anglesio and Sarah Glaze and Prafull Ghatage and Gregg S. Nelson and Martin Köbel
DOI: 10.1101/2020.08.21.20178830
08/2020

Histotype-specific analysis of acid ceramidase expression in ovarian cancer
Virchows Archiv
DOI: 10.1007/S00428-019-02728-0
2020

The Ovarian Tumour Tissue Analysis Consortium: Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) signature for high-grade serous ovarian cancer
Clinical Cancer Research
2020

ARID1A Mutations Promote P300-Dependent Endometrial Invasion through Super-Enhancer Hyperacetylation
Cell Reports
DOI: 10.1016/J.CELREP.2020.108366
2020

Application of the molecular Risk Stratification of the Endometrium to endometrioid Ovarian Carcinoma - a retrospective, international Multicenter Study
Geburtshilfe und Frauenheilkunde
DOI: 10.1055/S-0040-1718219
2020

Is endometriosis metastasizing? Shared somatic alterations suggest common origins across endometriotic lesions
Geburtshilfe und Frauenheilkunde
DOI: 10.1055/S-0040-1718045
2020

Endometrial cancer molecular risk stratification in endometrioid ovarian cancers: A novel application of precision medicine
Clinical Cancer Research
2020

Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer
Cancers
DOI: 10.3390/CANCERS12123828
2020

Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma
Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-20-1268
2020

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-20-0103
2020

STUDY IN PROGRESS: INTERNATIONAL RETROSPECTIVE STUDY ON LYMPHADENECTOMY IN ENDOMETRIOID OVARIAN CARCINOMA PATIENTS WITH EARLY STAGE DISEASE (LEOPARD)
International Journal of Gynecological Cancer
DOI: 10.1136/IJGC-2020-IGCS.394
2020

Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Gynecologic Oncology
DOI: 10.1016/J.YGYNO.2020.06.481
2020

Immunohistochemical Expression of L1CAM in Endometrioid Ovarian Cancer - A new Prognostic Marker?
Geburtshilfe und Frauenheilkunde
DOI: 10.1055/S-0040-1718139
2020

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
British Journal of Cancer
DOI: 10.1038/S41416-020-0900-0
2020

Molecular stratification of clear cell ovarian carcinomas
Geburtshilfe und Frauenheilkunde
DOI: 10.1055/S-0040-1718135
2020

PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer
Clinical Cancer Research
2020

Prognostic gene expression signature for high-grade serous ovarian cancer
Annals of Oncology
DOI: 10.1016/J.ANNONC.2020.05.019
2020

The molecular origin and taxonomy of mucinous ovarian carcinoma
Nature Communications
Dane Cheasley and Matthew J. Wakefield and Georgina L. Ryland and Prue E. Allan and Kathryn Alsop and Kaushalya C. Amarasinghe and Sumitra Ananda and Michael S. Anglesio and George Au-Yeung and Maret Böhm and David D. L. Bowtell and Alison Brand and Georgia Chenevix-Trench and Michael Christie and Yoke-Eng Chiew and Michael Churchman and Anna DeFazio and Renee Demeo and Rhiannon Dudley and Nicole Fairweather and Clare G. Fedele and Sian Fereday and Stephen B. Fox and C Blake Gilks and Charlie Gourley and Neville F. Hacker and Alison M. Hadley and Joy Hendley and Gwo-Yaw Ho and Siobhan Hughes and David G. Hunstman and Sally M. Hunter and Tom W. Jobling and Kimberly R. Kalli and Scott H. Kaufmann and Catherine J. Kennedy and Martin Köbel and Cecile Le Page and Jason Li and Richard Lupat and Orla M. McNally and Jessica N. McAlpine and Anne-Marie Mes-Masson and Linda Mileshkin and Diane M. Provencher and Jan Pyman and Kurosh Rahimi and Simone M. Rowley and Carolina Salazar and Goli Samimi
DOI: 10.1038/s41467-019-11862-x
09/2019

Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity
Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-18-3720
2019

TRANSLATING ENDOMETRIAL MOLECULAR RISK STRATIFICATION TO ENDOMETRIOID OVARIAN CARCINOMA: A NOVEL APPLICATION OF PRECISION MEDICINE
International Journal of Gynecological Cancer
DOI: 10.1136/IJGC-2019-IGCS.3
2019

Oncogenic mutations in histologically normal endometrium: the new normal?
The Journal of Pathology
DOI: 10.1002/PATH.5314
2019

APPLICATION OF PRECISION MEDICINE: CAN MOLECULAR RISK STRATIFICATION PROVIDE NEW MANAGEMENT OPTIONS FOR LOW STAGE ENDOMETRIOID OVARIAN CARCINOMA?
International Journal of Gynecological Cancer
DOI: 10.1136/IJGC-2019-ESGO.41
2019

THE PROGNOSTIC IMPACT OF SPHINGOSINE-KINASE 1 EXPRESSION (SPHK1) ON OVARIAN CANCER
International Journal of Gynecological Cancer
DOI: 10.1136/IJGC-2019-ESGO.882
2019

Iatrogenic endometriosis harbors somatic cancer-driver mutations
Human Reproduction
DOI: 10.1093/HUMREP/DEY332
2019

Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-18-3241
2019

HACE1 is a potential tumor suppressor in osteosarcoma
Cell Death and Disease
DOI: 10.1038/S41419-018-1276-4
2019

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases
Modern Pathology
DOI: 10.1038/S41379-019-0302-0
2019

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Cancers
Laboratory Investigation
2019

Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer
Journal of Cancer Research and Clinical Oncology
DOI: 10.1007/S00432-019-02986-0
2019

Optimized molecular risk stratification for ovarian endometrioid carcinomas
Modern Pathology
2019

Nuclear -catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome
Histopathology
DOI: 10.1111/HIS.13772
2019

You won't believe this old test … that does cheap single-cell mutation detection
The Journal of Pathology: Clinical Research
Martin Köbel and Michael S. Anglesio and James D. Brenton
DOI: 10.1002/cjp2.108
07/2018

Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging
Modern Pathology
Naveena Singh and Asma Faruqi and Friedrich Kommoss and W Glenn McCluggage and Giorgia Trevisan and Janine Senz and Amy Lum and C Blake Gilks and Michael Anglesio
DOI: 10.1038/modpathol.2017.159
04/2018

Cancer Associated Mutations in Eutopic Endometrium
Laboratory Investigation
2018

Capturing L1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers as a way to track tumor development
Clinical Cancer Research
2018

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Journal of Pathology Clinical Research
DOI: 10.1002/CJP2.109
2018

Somatic Cancer-Driver Alterations Among Benign Endometriosis Subtypes
Laboratory Investigation
2018

Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development
Ecancermedicalscience
DOI: 10.3332/ECANCER.2018.803
2018

A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer
Journal of Clinical Oncology
DOI: 10.1200/JCO.2018.36.15_SUPPL.5583
2018

Histotype classification of ovarian carcinoma: A comparison of approaches
Gynecologic Oncology
DOI: 10.1016/J.YGYNO.2018.08.016
2018

Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage
International Journal of Gynecological Pathology
DOI: 10.1097/PGP.0000000000000429
2018

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Cell
DOI: 10.1016/J.CELL.2018.03.073
2018

CLINICAL AND MOLECULAR CHARACTERIZATION OF SYNCHRONOUS ENDOMETRIAL AND OVARIAN CARCINOMAS
International Journal of Gynecological Cancer
2018

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Nature Genetics
Yi Kan Wang and Ali Bashashati and Michael S Anglesio and Dawn R Cochrane and Diljot S Grewal and Gavin Ha and Andrew McPherson and Hugo M Horlings and Janine Senz and Leah M Prentice and Anthony N Karnezis and Daniel Lai and Mohamed R Aniba and Allen W Zhang and Karey Shumansky and Celia Siu and Adrian Wan and Melissa K McConechy and Hector Li-Chang and Alicia Tone and Diane Provencher and Manon de Ladurantaye and Hubert Fleury and Aikou Okamoto and Satoshi Yanagida and Nozomu Yanaihara and Misato Saito and Andrew J Mungall and Richard Moore and Marco A Marra and C Blake Gilks and Anne-Marie Mes-Masson and Jessica N McAlpine and Samuel Aparicio and David G Huntsman and Sohrab P Shah
DOI: 10.1038/ng.3849
06/2017

Cancer-Associated Mutations in Endometriosis without Cancer
New England Journal of Medicine
DOI: 10.1056/NEJMOA1614814
2017

APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner
Gynecologic Oncology
DOI: 10.1016/J.YGYNO.2017.10.016
2017

Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries
Histopathology
DOI: 10.1111/HIS.13327
2017

EXPRESSION OF ACID CERAMIDASE (ASAH1) AS A PROGNOSTIC FACTOR IN OVARIAN CANCER
International Journal of Gynecological Cancer
2017

Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C > G FOXL2 mutation
Plos One
DOI: 10.1371/JOURNAL.PONE.0178989
2017

Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma
Molecular Cancer Research
DOI: 10.1158/1541-7786.MCR-16-0132
2017

LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers
Gynecologic Oncology
DOI: 10.1016/J.YGYNO.2017.09.032
2017

Enhanced GAB2 Expression Is Associated with Improved Survival in High-grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition (vol 14, pg 1495, 2015)
Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.MCT-17-0067
2017

Confirmation of ProMisE: A Simple, Genomics-Based Clinical Classifier for Endometrial Cancer
Cancer
DOI: 10.1002/CNCR.30496
2017

Endometriosis-associated Ovarian Cancers
Clinical Obstetrics and Gynecology
DOI: 10.1097/GRF.0000000000000320
2017

Genomic consequences of aberrant DNA repair stratify ovarian cancer histotypes
Cancer Research
DOI: 10.1158/1538-7445.AM2016-LB-324
2016

Synchronous ovarian and endometrial carcinomas: The case for pseudo-metastasis
Clinical Cancer Research
DOI: 10.1158/1557-3265.OVCA15-PR07
2016

Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction
Plos One
DOI: 10.1371/JOURNAL.PONE.0153844
2016

IS ENDOMETRIOSIS A NEOPLASM AND IS THERE AN OPPORTUNITY FOR A BIOLOGICALLY INFORMED CLASSIFICATION SYSTEM?
International Journal of Gynecological Cancer
2016

Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver (vol 20, pg 6618, 2014)
Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-16-0992
2016

Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality
Journal of the National Cancer Institute
DOI: 10.1093/JNCI/DJV428
2016

Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines
American Journal of Cancer Research
2016

Genomics analyses of less common epithelial ovarian cancer subtypes
Clinical Cancer Research
DOI: 10.1158/1557-3265.OVCA15-B08
2016

BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer
International Journal of Gynecological Cancer
DOI: 10.1097/IGC.0000000000000698
2016

Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
Anglesio MS and Bashashati A and Wang YK and Senz J and Ha G and Yang W and Aniba MR and Prentice LM and Farahani H and Li Chang H and Karnezis AN and Marra MA and Yong PJ and Hirst M and Gilks B and Shah SP and Huntsman DG
DOI: 10.1002/path.4516
PubMed: 25692284
06/2015

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Davis SJ and Sheppard KE and Anglesio MS and George J and Traficante N and Fereday S and Intermaggio MP and Menon U and Gentry-Maharaj A and Lubinski J and Gronwald J and Pearce CL and Pike MC and Wu A and Kommoss S and Pfisterer J and du Bois A and Hilpert F and Ramus SJ and Bowtell DD and Huntsman DG and Pearson RB and Simpson KJ and Campbell IG and Gorringe KL
DOI: 10.1158/1535-7163.MCT-15-0039
PubMed: 25852062
06/2015

Recurrent DICER1 Hotspot Mutations in Endometrial Tumours And Their Impact on MicroRNA Biogenesis.
Chen J and Wang Y and McMonechy MK and Anglesio MS and Yang W and Senz J and Maines-Bandiera S and Rosner J and Trigo-Gonzalez G and Grace Cheng SW and Kim J and Matzuk MM and Morin GB and Huntsman DG
PubMed: 26033159
06/2015

The somatic mutational landscape of endometriosis associated ovarian cancers and precursor lesions
Clinical Cancer Research
DOI: 10.1158/1557-3265.OVCASYMP14-AS18
2015

The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors
Neoplasia
DOI: 10.1016/J.NEO.2015.08.003
2015

Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers
American Journal of Surgical Pathology
DOI: 10.1097/PAS.0000000000000476
2015

The oncogenic role of DICER1 RNase IIIb domain mutations in ovarian sertoli-leydig cell tumors
Clinical Cancer Research
DOI: 10.1158/1557-3265.OVCASYMP14-POSTER-BIOL-1349
2015

Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma
International Journal of Gynecological Cancer
DOI: 10.1097/IGC.0000000000000492
2015

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes
Oncotarget
DOI: 10.18632/ONCOTARGET.5438
2015

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R and Kommoss S and Winterhoff BJ and Kipp BR and Garcia JJ and Voss J and Halling K and Karnezis A and Senz J and Yang W and Prigge ES and Reuschenbach M and Doeberitz MV and Gilks BC and Huntsman DG and Bakkum-Gamez J and McAlpine JN and Anglesio MS
DOI: 10.1186/s12885-015-1421-8
PubMed: 25986173
2015

Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis
The Journal of Pathology
DOI: 10.1002/PATH.4569
2015

Molecular Characteristics of Mixed Ovarian Carcinomas
Modern Pathology
2015

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C and Chiew YE and George J and Etemadmoghadam D and Anglesio MS and Sharma R and Russell P and Kennedy C and Fereday S and Hung J and Galletta L and Hogg R and Wain GV and Brand A and Balleine R and MacConaill L and Palescandolo E and Hunter SM and Campbell I and Dobrovic A and Wong SQ and Do H and Clarke CL and Harnett PR and Bowtell DD and deFazio A and Australian Ovarian Cancer Study (AOCS)
DOI: 10.1158/1078-0432.CCR-14-1292
PubMed: 25316818
12/2014

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M and Madore J and Ramus SJ and Clarke BA and Pharoah PD and Deen S and Bowtell DD and Odunsi K and Menon U and Morrison C and Lele S and Bshara W and Sucheston L and Beckmann MW and Hein A and Thiel FC and Hartmann A and Wachter DL and Anglesio MS and Høgdall E and Jensen A and Høgdall C and Kalli KR and Fridley BL and Keeney GL and Fogarty ZC and Vierkant RA and Liu S and Cho S and Nelson G and Ghatage P and Gentry-Maharaj A and Gayther SA and Benjamin E and Widschwendter M and Intermaggio MP and Rosen B and Bernardini MQ and Mackay H and Oza A and Shaw P and Jimenez-Linan M and Driver KE and Alsop J and Mack M and Koziak JM and Steed H and Ewanowich C and DeFazio A and Chenevix-Trench G and Fereday S and Gao B and Johnatty SE and George J and Galletta L and AOCS Study Group and Goode EL and Kjær SK and Huntsman DG and Fasching PA and Moysich KB and Brenton JD and Kelemen LE
DOI: 10.1038/bjc.2014.567
PubMed: 25349970
12/2014

Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.
Leung AW and Kalra J and Santos ND and Bally MB and Anglesio MS
DOI: 10.2217/nnm.13.220
PubMed: 24746193
03/2014

A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary.
Kommoss S and Gilks CB and Penzel R and Herpel E and Mackenzie R and Huntsman D and Schirmacher P and Anglesio M and Schmidt D and Kommoss F
DOI: 10.1111/his.12253
PubMed: 24192202
02/2014

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC and Hennessy BT and Leung S and Wang Y and Ju Z and McGahren M and Kalloger SE and Finlayson S and Stemke-Hale K and Lu Y and Zhang F and Anglesio MS and Gilks B and Mills GB and Huntsman DG and Carey MS
DOI: 10.1186/1471-2407-14-120
PubMed: 24559118
2014

PROGNOSTIC MARKERS FOR HIGH GRADE SEROUS OVARIAN CANCER AND VALIDATION USING LARGE SCALE NANOSTRING EXPRESSION PROFILING: AN OTTA CONSORTIUM STUDY
International Journal of Gynecological Cancer
2014

Recurrent DICER1 hotspot mutations in endometrial cancer and their impact on microRNA biogenesis
Cancer Research
DOI: 10.1158/1538-7445.AM2014-544
2014

ENHANCED GAB2 EXPRESSION IS CHARACTERISTIC OF A CLINICALLY DISTINCT PI3K-DEPENDENT SUBTYPE OF HIGH-GRADE SEROUS AND ENDOMETRIOID OVARIAN CANCER
International Journal of Gynecological Cancer
2014

PRACTICAL TECHNOLOGIES FOR MOLECULAR-BASED CLASSIFICATION TO IMPROVE MANAGEMENT IN WOMEN WITH ENDOMETRIAL CANCER
International Journal of Gynecological Cancer
2014

The somatic mutational landscape of ovarian clear cell carcinoma and its precursor lesions
Cancer Research
DOI: 10.1158/1538-7445.AM2014-LB-312
2014

EXOME SEQUENCING OF LOW GRADE SEROUS OVARIAN TUMOURS
International Journal of Gynecological Cancer
2014

Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.
Kommoss S and Gilks CB and Kommoss F and Chow C and Hilpert F and du Bois A and Köbel M and Huntsman DG and Anglesio M and Kalloger SE and Pfisterer J
DOI: 10.1111/his.12219
PubMed: 24033430
11/2013

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
Bashashati A and Ha G and Tone A and Ding J and Prentice LM and Roth A and Rosner J and Shumansky K and Kalloger S and Senz J and Yang W and McConechy M and Melnyk N and Anglesio M and Luk MT and Tse K and Zeng T and Moore R and Zhao Y and Marra MA and Gilks B and Yip S and Huntsman DG and McAlpine JN and Shah SP
DOI: 10.1002/path.4230
PubMed: 23780408
09/2013

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W and Köbel M and Longacre TA and Bowtell DD and deFazio A and Goodman MT and Høgdall E and Deen S and Wentzensen N and Moysich KB and Brenton JD and Clarke BA and Menon U and Gilks CB and Kim A and Madore J and Fereday S and George J and Galletta L and Lurie G and Wilkens LR and Carney ME and Thompson PJ and Matsuno RK and Kjær SK and Jensen A and Høgdall C and Kalli KR and Fridley BL and Keeney GL and Vierkant RA and Cunningham JM and Brinton LA and Yang HP and Sherman ME and García-Closas M and Lissowska J and Odunsi K and Morrison C and Lele S and Bshara W and Sucheston L and Jimenez-Linan M and Driver K and Alsop J and Mack M and McGuire V and Rothstein JH and Rosen BP and Bernardini MQ and Mackay H and Oza A and Wozniak EL and Benjamin E and Gentry-Maharaj A and Gayther SA and Tinker AV and Prentice LM and Chow C and Anglesio MS and Johnatty SE and Chenevix-Trench G and Whittemore AS and Pharoah PD and Goode EL and Huntsman DG and Ramus SJ
DOI: 10.1016/S1470-2045(13)70253-5
PubMed: 23845225
08/2013

FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines.
Kommoss S and Anglesio MS and Mackenzie R and Yang W and Senz J and Ho J and Bell L and Lee S and Lorette J and Huntsman DG and Blake Gilks C
DOI: 10.1038/modpathol.2012.226
PubMed: 23348906
06/2013

Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage.
Anglesio MS and Wang Y and Yang W and Senz J and Wan A and Heravi-Moussavi A and Salamanca C and Maines-Bandiera S and Huntsman DG and Morin GB
DOI: 10.1002/path.4135
PubMed: 23132766
02/2013

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Anglesio MS and Kommoss S and Tolcher MC and Clarke B and Galletta L and Porter H and Damaraju S and Fereday S and Winterhoff BJ and Kalloger SE and Senz J and Yang W and Steed H and Allo G and Ferguson S and Shaw P and Teoman A and Garcia JJ and Schoolmeester JK and Bakkum-Gamez J and Tinker AV and Bowtell DD and Huntsman DG and Gilks CB and McAlpine JN
DOI: 10.1002/path.4088
PubMed: 22899400
01/2013

Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.
Anglesio MS and Wiegand KC and Melnyk N and Chow C and Salamanca C and Prentice LM and Senz J and Yang W and Spillman MA and Cochrane DR and Shumansky K and Shah SP and Kalloger SE and Huntsman DG
PubMed: 24116245
2013

Rapid RNA-based histotyping of ovarian carcinomas
Clinical Cancer Research
DOI: 10.1158/1078-0432.OVCA13-B14
2013

Defining ovarian mucinous tumors: Cancer genes and heterogeneity
Clinical Cancer Research
DOI: 10.1158/1078-0432.OVCA13-A18
2013

Type-specific cell line models for type-specific ovarian cancer research.
Anglesio MS and Wiegand KC and Melnyk N and Chow C and Salamanca C and Prentice LM and Senz J and Yang W and Spillman MA and Cochrane DR and Shumansky K and Shah SP and Kalloger SE and Huntsman DG
DOI: 10.1371/journal.pone.0072162
PubMed: 24023729
2013

Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.
Townsend KN and Spowart JE and Huwait H and Eshragh S and West NR and Elrick MA and Kalloger SE and Anglesio M and Watson PH and Huntsman DG and Lum JJ
DOI: 10.1371/journal.pone.0082406
PubMed: 24376535
2013

Molecular profiling of low grade serous ovarian tumors
Clinical Cancer Research
DOI: 10.1158/1078-0432.OVCA13-A13
2013

A CURRENT PERSPECTIVE ON THE PATHOLOGICAL ASSESSMENT OF ADULT-TYPE GRANULOSA CELL TUMORS OF THE OVARY
International Journal of Gynecological Cancer
2013

The ovarian tumor tissue analysis (OTTA) consortium
Clinical Cancer Research
DOI: 10.1158/1078-0432.OVCA13-A27
2013

The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer.
Spowart JE and Townsend KN and Huwait H and Eshragh S and West NR and Ries JN and Kalloger S and Anglesio M and Gorski SM and Watson PH and Gilks CB and Huntsman DG and Lum JJ
DOI: 10.1002/path.4090
PubMed: 22926683
12/2012

Cytokine gene expression signature in ovarian clear cell carcinoma.
Yanaihara N and Anglesio MS and Ochiai K and Hirata Y and Saito M and Nagata C and Iida Y and Takakura S and Yamada K and Tanaka T and Okamoto A
DOI: 10.3892/ijo.2012.1533
PubMed: 22751940
09/2012

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
Cowin PA and George J and Fereday S and Loehrer E and Van Loo P and Cullinane C and Etemadmoghadam D and Ftouni S and Galletta L and Anglesio MS and Hendley J and Bowes L and Sheppard KE and Christie EL and Pearson RB and Harnett PR and Heinzelmann-Schwarz V and Friedlander M and McNally O and Quinn M and Campbell P and deFazio A and Bowtell DD and Australian Ovarian Cancer Study
DOI: 10.1158/0008-5472.CAN-12-0203
PubMed: 22896685
08/2012

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
Heravi-Moussavi A and Anglesio MS and Cheng SW and Senz J and Yang W and Prentice L and Fejes AP and Chow C and Tone A and Kalloger SE and Hamel N and Roth A and Ha G and Wan AN and Maines-Bandiera S and Salamanca C and Pasini B and Clarke BA and Lee AF and Lee CH and Zhao C and Young RH and Aparicio SA and Sorensen PH and Woo MM and Boyd N and Jones SJ and Hirst M and Marra MA and Gilks B and Shah SP and Foulkes WD and Morin GB and Huntsman DG
DOI: 10.1056/NEJMoa1102903
PubMed: 22187960
01/2012

FOXL2 Molecular Testing in the Diagnosis of Ovarian Neoplasms
Laboratory Investigation
2012

Benign serous ovarian tumour: a redefining moment?
Hunter S and Gorringe K and Anglesio M and Sharma R and Gilks B and deFazio A and Huntsman D and Campbell I
2012

Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
Hunter SM and Anglesio MS and Sharma R and Gilks CB and Melnyk N and Chiew YE and deFazio A and Australian Ovarian Cancer Study Group and Longacre TA and Huntsman DG and Gorringe KL and Campbell IG
DOI: 10.1158/1078-0432.CCR-11-2080
PubMed: 21976534
12/2011

Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.
Anglesio MS and Carey MS and Köbel M and Mackay H and Huntsman DG and Vancouver Ovarian Clear Cell Symposium Speakers
DOI: 10.1016/j.ygyno.2011.01.005
PubMed: 21276610
05/2011

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK and Anglesio MS and Kalloger SE and Yang W and Senz J and Chow C and Heravi-Moussavi A and Morin GB and Mes-Masson AM and Australian Ovarian Cancer Study Group and Carey MS and McAlpine JN and Kwon JS and Prentice LM and Boyd N and Shah SP and Gilks CB and Huntsman DG
DOI: 10.1002/path.2848
PubMed: 21381030
04/2011

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS and George J and Kulbe H and Friedlander M and Rischin D and Lemech C and Power J and Coward J and Cowin PA and House CM and Chakravarty P and Gorringe KL and Campbell IG and Australian Ovarian Cancer Study Group and Okamoto A and Birrer MJ and Huntsman DG and de Fazio A and Kalloger SE and Balkwill F and Gilks CB and Bowtell DD
DOI: 10.1158/1078-0432.CCR-10-3314
PubMed: 21343371
04/2011

Using the right tools: A catalog of ovarian cancer cell lines by subtype
Cancer Research
DOI: 10.1158/1538-7445.AM2011-4289
2011

Identification of somatic mutations of the PPP2R1A gene in subtypes of endometrial and ovarian carcinomas
Cancer Research
DOI: 10.1158/1538-7445.AM2011-924
2011

Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å and Anglesio MS and George J and Cowin PA and Johnstone CN and House CM and Sheppard KE and Etemadmoghadam D and Melnyk N and Rustgi AK and Phillips WA and Johnsen H and Holm R and Kristensen GB and Birrer MJ and Australian Ovarian Cancer Study Group and Pearson RB and Børresen-Dale AL and Huntsman DG and deFazio A and Creighton CJ and Smyth GK and Bowtell DD
DOI: 10.1371/journal.pone.0018064
PubMed: 21533284
2011

Benign ovarian serous tumors: A redefining moment
Cancer Research
DOI: 10.1158/1538-7445.AM2011-LB-271
2011

ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC and Shah SP and Al-Agha OM and Zhao Y and Tse K and Zeng T and Senz J and McConechy MK and Anglesio MS and Kalloger SE and Yang W and Heravi-Moussavi A and Giuliany R and Chow C and Fee J and Zayed A and Prentice L and Melnyk N and Turashvili G and Delaney AD and Madore J and Yip S and McPherson AW and Ha G and Bell L and Fereday S and Tam A and Galletta L and Tonin PN and Provencher D and Miller D and Jones SJ and Moore RA and Morin GB and Oloumi A and Boyd N and Aparicio SA and Shih IeM and Mes-Masson AM and Bowtell DD and Hirst M and Gilks B and Marra MA and Huntsman DG
DOI: 10.1056/NEJMoa1008433
PubMed: 20942669
10/2010

Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.
Gorringe KL and George J and Anglesio MS and Ramakrishna M and Etemadmoghadam D and Cowin P and Sridhar A and Williams LH and Boyle SE and Yanaihara N and Okamoto A and Urashima M and Smyth GK and Campbell IG and Bowtell DD and Australian Ovarian Cancer Study
DOI: 10.1371/journal.pone.0011408
PubMed: 20844748
2010

Profiling the cancer genome.
Cowin PA and Anglesio M and Etemadmoghadam D and Bowtell DD
DOI: 10.1146/annurev-genom-082509-141536
PubMed: 20590430
2010

Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL and Ramakrishna M and Williams LH and Sridhar A and Boyle SE and Bearfoot JL and Li J and Anglesio MS and Campbell IG
DOI: 10.1002/gcc.20694
PubMed: 19603523
10/2009

A dysregulated pathway underlying a novel molecular subtype of ovarian cancer
European Journal of Cancer, Supplement
DOI: 10.1016/S1359-6349(09)70314-3
2009

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
Anglesio MS and Arnold JM and George J and Tinker AV and Tothill R and Waddell N and Simms L and Locandro B and Fereday S and Traficante N and Russell P and Sharma R and Birrer MJ and AOCS Study Group and deFazio A and Chenevix-Trench G and Bowtell DD
DOI: 10.1158/1541-7786.MCR-08-0193
PubMed: 19010816
11/2008

The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers.
Zhang L and Anglesio MS and O'Sullivan M and Zhang F and Yang G and Sarao R and Mai PN and Cronin S and Hara H and Melnyk N and Li L and Wada T and Liu PP and Farrar J and Arceci RJ and Sorensen PH and Penninger JM
DOI: 10.1038/nm1621
PubMed: 17694067
09/2007

Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species.
Evdokimova V and Ruzanov P and Anglesio MS and Sorokin AV and Ovchinnikov LP and Buckley J and Triche TJ and Sonenberg N and Sorensen PH
DOI: 10.1128/MCB.26.1.277-292.2006
PubMed: 16354698
01/2006

Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney.
Anglesio MS and Evdokimova V and Melnyk N and Zhang L and Fernandez CV and Grundy PE and Leach S and Marra MA and Brooks-Wilson AR and Penninger J and Sorensen PH
DOI: 10.1093/hmg/ddh215
PubMed: 15254018
09/2004